Article Text

Download PDFPDF

Original research
ADAPT technique with ACE68 and ACE64 reperfusion catheters in ischemic stroke treatment: results from the PROMISE study
  1. Peter Schramm1,
  2. Pedro Navia2,
  3. Rosario Papa3,
  4. Joaquin Zamarro4,
  5. Alejandro Tomasello5,6,
  6. Werner Weber7,
  7. Jens Fiehler8,
  8. Patrik Michel9,
  9. Vitor M Pereira10,
  10. Timo Krings11,12,
  11. Jan Gralla13,
  12. Paola Santalucia14,
  13. Laurent Pierot15,
  14. T H Lo16
  1. 1 Department of Neuroradiology, University Medical Center Schleswig-Holstein, Luebeck, Germany
  2. 2 Radiology-Interventional Neuroradiology, Hospital Universitario Donostia, San Sebastian, Spain
  3. 3 Radiology, Universita degli Studi di Messina, Messina, Italy
  4. 4 Interventional Neuroradiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
  5. 5 Department of Radiology, Section of Interventional Neuroradiology, Barcelona, Spain
  6. 6 Vall d’Hebron Research Institute (VHIR), Barcelona, Spain
  7. 7 Radiology and Neuroradiology, Ruhr-University Bochum, University Medical Center Langendreer, Bochum, Germany
  8. 8 Department of Neuroradiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
  9. 9 University of Lausanne, Lausanne, Switzerland
  10. 10 Medical Imaging, Toronto Western Hospital, Toronto, Ontario, Canada
  11. 11 Division of Neuroradiology, Department of Medical Imaging, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada
  12. 12 Division of Neurosurgery, Department of Surgery, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada
  13. 13 Department for Diagnostic and Interventional Neuroradiology, Inselspital, University of Bern, Bern, Switzerland
  14. 14 IRCCS Centro Neurolesi Bonino Pulejo, Piemonte Hospital, Messina, Italy
  15. 15 Radiology, University Hospital Reims, Reims, France
  16. 16 Department of Interventional Radiology and Interventional Neuroradiology, Universitair Medisch Centrum Utrecht, Utrecht, The Netherlands
  1. Correspondence to Professor Peter Schramm, Department of Neuroradiology, University Medical Center Schleswig-Holstein, Luebeck 23538, Germany; Peter.Schramm{at}uksh.de

Abstract

Background and purpose The recent randomized trials demonstrated the benefit of mechanical thrombectomy in stroke therapy. However, treatment using different strategies is an ongoing area of investigation. The PROMISE study analyzed the safety and effectiveness of the Penumbra System with the ACE68 and ACE64 reperfusion catheters in aspiration thrombectomy of stroke, using A Direct Aspiration First Pass Technique (ADAPT).

Methods PROMISE was a prospective study which enrolled 204 patients with intracranial anterior circulation large vessel occlusion (LVO) ischemic stroke in 20 centers from February 2016 to May 2017. Initial treatment was with the ACE68/ACE64 catheters within 6 hours of symptom onset. Imaging and safety review was performed by an independent Core Laboratory and a Clinical Events Committee. The primary angiographic outcome was revascularization to mTICI 2b-3 at immediate post-procedure and the primary clinical outcome was 90-day modified Rankin Scale (mRS) score ≤2. Safety assessment included device- and procedure-related serious adverse events (SAEs), symptomatic intracranial hemorrhage (sICH), mortality, and embolization of new territory (ENT).

Results Enrolled patients had a median age of 74 (IQR 65–80) years and a median admission NIHSS of 16 (IQR 11–20). The post-procedure mTICI 2b-3 revascularization rate was 93.1% and the 90-day mRS 0–2 rate was 61%. Device- and procedure-related SAEs at 24 hours occurred in 1.5% and 3.4%, respectively, 90-day mortality was 7.5%, sICH occurred in 2.9% while ENT occurred in 1.5%.

Conclusions For frontline therapy of LVO stroke, the ACE68/ACE64 catheters for aspiration thrombectomy were found to be safe and showed similar efficacy to randomized trials using other revascularization techniques.

Clinical Trial Registration NCT02678169; Pre-results.

  • stroke
  • thrombectomy
  • device

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors All authors made a substantial, direct, and intellectual contribution to the work.

  • Funding This study was funded by Penumbra, Inc (9508).

  • Competing interests The following investigators report financial conflicts with this study: PS reports being a consultant for Penumbra and Stryker, and receiving research support from Penumbra, Philips, and Siemens. RP reports proctoring and consulting for Medtronic, Penumbra, and Implemed. WW reports a proctor agreement with Microvention/Terumo, Medtronic, and Phenox, and being a consultant with Penumbra (speaker and chairman fees). JF reports being a consultant for Penumbra, Acandis, Boehringer Ingelheim, Cerenovus, Covidien, Medtronic, Microvention, Route92, and Stryker, and receiving research support from the German Ministry of Science and Education (BMBF), German Ministry of Economy and Innovation (BMWi), German Research Foundation (DFG), European Union (EU), Hamburgische Investitions- und Förderbank (IFB), Medtronic, Microvention, Philips, and Stryker. PM reports speaker and consulting fees from Medtronic, used for stroke education. TK and VMP received funding from the sponsor for imaging core lab oratory activities. VMP reports being a consultant for Penumbra (PROMISE study), Medtronic, Stryker, and Neurovasc. LP received funding from Penumbra for CEC activities and is a consultant for Balt, Cerenovus/Neuravi, and Microvention.

  • Patient consent Not required.

  • Ethics approval The local Ethics Committees approved the study, and the patients or their representatives provided written informed consent, according to local regulations.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement Because of the sensitive nature of the data collected for this study, requests to access the dataset from qualified researchers trained in human subject confidentiality protocols may be sent to Penumbra, Inc. at promise@penumbrainc.com.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.